Imv Inc (NASDAQ: IMV) is making a run for the top in the market today, and for good reason, the company announced progress made in its COVID-19 program. Here’s what’s going on:
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
IMV Stock Is Flying On COVID-19 News
In the press release, IMV announced that it has made rapid progress in the development of its COVID-19 vaccine, and the progress is compelling.
First and foremost, the company is working to move forward with clinical studies and has made a big step toward that goal. In fact, the design of the Phase 1 study is complete and has been agreed to by Health Canada. The study will assess the safety and immunogenicity of DPX-COVID-19, in 84 healthy adults ranging in age from 18 to 56.
The company also said that in the trial, it will test two dose levels, assessing which dose level has the strongest safety and immunogenicity profile for future studies.
IMV went on to remind investors of its positive results seen in a previous RSV study, and believes that these results point to likely positive results in the COVID-19 study. In a statement, Frederic Ors, Chief Executive Officer at IMV, had the following to offer:
We are working closely with regulatory agencies and our collaborators to initiate clinical studies as quickly as possible. The design of the phase 1 clinical study, agreed with Health Canada, is a randomized controlled study, assessing the safety and immunogenicity of DPX-COVID-19, in 84 healthy adults across two age cohorts: (1) adults between 18-55 years old inclusive and (2) 56 and above. Two dose levels of DPX-COVID-19 will be tested (25μg or 50μg). We are pleased that Health Canada has welcomed the design of a phase 1 trial that includes this vulnerable population.
Clinical results have shown our DPX-based vaccine against RSV demonstrated a unique ability to generate safe and long-lasting immune responses in older adults.
This Is Great News
The news released by IMV today is overwhelmingly positive. We all know that COVID-19 cases are growing again as the United States continues to reopen. We all know that we need new weapons in the fight against the pandemic, and we all know that the companies that are successful in producing vaccines and treatments will reap the rewards.
With this announcement, Phase 1 studies are likely just around the corner for the company’s COVID-19 vaccine. This is great news for IMV stock and all who own it.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Don’t Miss The Next Big Story
Join our free mailing list below to receive real-time news alerts!